Studies have shown that overexpression of SEPT9 attenuates myofibroblast biomarkers α-SMA and Col1a1 expression induced by TGF-β1, goes together with the upregulation of proteins associated with apoptosis, and slows down activation of hepatic stellate cells, so drugs that suppress the methylation and elevate the expression of SEPT9 hold promise for clinical application in the management of hepatic fibrosis [25]. This evidence concerns the gene COL1A1 and Hepatic fibrosis.